CAJ | 학술논문

背景与目的小细胞肺癌约占全部肺癌的15%，化疗是其主要的治疗方法之一，虽然早期对一线化疗方案敏感，但极易出现多药耐药而导致治疗失败。前期基因芯片发现SPHK1与小细胞肺癌的耐药性相关，本研究进一步探讨SPHK1在小细胞肺癌多药耐药中的作用。方法首先通过QRT-PCR和Western blot从基因和蛋白水平检测化疗敏感细胞株H69及多药耐药细胞株H69AR中SPHK1的差异表达；转染siRNA下调H69AR细胞中的SPHK1的表达，通过CCK8检测细胞对各种化疗药物（ADM, DDP, VP-16）的敏感性变化，流式细胞仪检测细胞周期及凋亡的变化。同时收集小细胞肺癌化疗前组织和血液标本，将其分为化疗敏感组和耐药组，QRT-PCR检测小细胞肺癌患者血液标本中SPHK1的表达，免疫组化法检测小细胞肺癌患者组织标本中SPHK1的表达，分析SPHK1与小细胞肺癌患者预后相关性。结果 SPHK1在耐药细胞H69AR中的表达明显高于H69，下调H69AR中SPHK1的表达能够增加细胞对化疗药物的敏感性，促进细胞的凋亡，细胞周期发生G0/G1期阻滞，SPHK1在小细胞肺癌耐药患者中的表达较敏感患者明显增加，SPHK1的表达与患者的性别、年龄无关，与疾病的分期、对化疗的敏感性及生存时间密切相关，差异具有统计学意义（P<0.05）。结论 SPHK1参与调节小细胞肺癌多药耐药，SPHK1可作为评估小细胞肺癌化疗敏感性及临床预后的潜在靶基因。
배경여목적소세포폐암약점전부폐암적15%，화료시기주요적치료방법지일，수연조기대일선화료방안민감，단겁역출현다약내약이도치치료실패。전기기인심편발현SPHK1여소세포폐암적내약성상관，본연구진일보탐토SPHK1재소세포폐암다약내약중적작용。방법수선통과QRT-PCR화Western blot종기인화단백수평검측화료민감세포주H69급다약내약세포주H69AR중SPHK1적차이표체；전염siRNA하조H69AR세포중적SPHK1적표체，통과CCK8검측세포대각충화료약물（ADM, DDP, VP-16）적민감성변화，류식세포의검측세포주기급조망적변화。동시수집소세포폐암화료전조직화혈액표본，장기분위화료민감조화내약조，QRT-PCR검측소세포폐암환자혈액표본중SPHK1적표체，면역조화법검측소세포폐암환자조직표본중SPHK1적표체，분석SPHK1여소세포폐암환자예후상관성。결과 SPHK1재내약세포H69AR중적표체명현고우H69，하조H69AR중SPHK1적표체능구증가세포대화료약물적민감성，촉진세포적조망，세포주기발생G0/G1기조체，SPHK1재소세포폐암내약환자중적표체교민감환자명현증가，SPHK1적표체여환자적성별、년령무관，여질병적분기、대화료적민감성급생존시간밀절상관，차이구유통계학의의（P<0.05）。결론 SPHK1삼여조절소세포폐암다약내약，SPHK1가작위평고소세포폐암화료민감성급림상예후적잠재파기인。
Background and objective Lung cancer is the leading cause of cancer-related deaths worldwide. Ap-proximately 15%of all histological types consist of small cell lung cancer (SCLC). Chemotherapy is one of the major treatment method. hTough the current ifrst-line standard chemotherapy regimen for SCLC is active in most SCLC cases, however the disease recurs shortly atfer the ifrst successful treatment with multi-drug resistance (MDR) phenotype. Our previously study showed that SPHK1 was associated with MDR in SCLC. hTe aim of this study is to investigate the role of sphingosine kinase 1 (SPHK1) showed in small cell lung multi-drug resistance. Methods Firstly, the analysis of QRT-PCR and Western blot were used to study differential expression of SPHK1 from mRNA and protein levels in both the H69 and H69AR cell lines. hTen, Downregulation of SPHK1 by transfection with siRNA in H69AR. Moreover, the sensitivities of cells to chemotherapy drugs such as ADM, DDP, VP-16 were detected by CCK8 assay. hTe change of cell cycle and apoptosis rate were detected by lfow cytometry. Meanwhile, expression of SPHK1 in clinical specimens were detected by QT-PCR and immunohistochemistry. Re-lation of SPHK1 expression with clinicopathological features and prognosis of patients was studied. Results hTe expression of SPHK1 was signiifcantly decreased in H69AR cells that in the H69 cells. hTe sensitivities of H69AR cells to chemotherapy drugs were increased when up-regulated the expression of SPHK1, enforced SPHK1 expression increased cell apoptosis and the cell cycle arrest in G0/G1 phase in H69AR cells, the expression of SPHK1 was not associated with gender, age, but signiif-cantly correlated with clinical stage, chemosensitivity and overall survival (P<0.05). Conclusion Our results suggest that SPHK1 is involved in the regulation of small cell lung cancer multi-drug resistance, SPHK1 may be as potentialtarget gene to evaluate the chemosensitivity and clinical prognostic for SCLC.